TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate responses to particle-mediated MPLA-CpG co-presentation-Reference-Cited by-同舟云学术

TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate responses to particle-mediated MPLA-CpG co-presentation

Published:2021-01-15 Issue:3 Volume:7 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Pradhan P.¹²³^ORCID,Toy R.¹^ORCID,Jhita N.⁴^ORCID,Atalis A.¹^ORCID,Pandey B.¹^ORCID,Beach A.¹,Blanchard E. L.¹,Moore S. G.²^ORCID,Gaul D. A.²^ORCID,Santangelo P. J.¹^ORCID,Shayakhmetov D. M.⁴⁵^ORCID,Roy K.¹²³^ORCID

Affiliation:

1. The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.

2. The Parker H. Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA, USA.

3. Marcus Center for Therapeutic Cell Characterization and Manufacturing, Georgia Institute of Technology, Atlanta, GA, USA.

4. Lowance Center of Human Immunology, Department of Pediatrics and Medicine, Emory University School of Medicine, Atlanta, GA, USA.

5. Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.

Abstract

TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate immune responses to particle-delivered MPLA and CpG.

Funder

NIAID

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference54 articles.

1. Key roles of adjuvants in modern vaccines

2. Adjuvants for cancer vaccines

3. Aluminum adjuvants of vaccines injected into the muscle: Normal fate, pathology and associated disease

4. Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses

5. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanocarrier design for pathogen-inspired innate immune agonist delivery;Trends in Immunology;2024-09

2. Engineering approaches for innate immune-mediated tumor microenvironment remodeling;Immuno-Oncology and Technology;2024-03

3. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists;ACS Nano;2024-02-22

4. Emerging nanoparticle platforms for CpG oligonucleotide delivery;Biomaterials Science;2024

5. Single-cell epitope-transcriptomics reveal lung stromal and immune cell response kinetics to nanoparticle-delivered RIG-I and TLR4 agonists;Biomaterials;2023-06